FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Merck & Liptruzet Recall

Liptruzet (ezetimibe and atorvastin) tablets,10 mg/20 mg, a) 30 count blister (NDC 6…

Merck & Co Inc · Whitehouse Station, NJ

Risk level
Class III
Reported by FDA
May 14, 2014
Recall ID
D-1310-2014
Check your lot numberHow we source this data

Summary

Merck & recalled Liptruzet starting Jan 13, 2014. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-1310-2014 on May 14, 2014. Reason: This recall of LIPTRUZET is being initiated due to packaging defects. Some of the outer laminate foil pouches allowed in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product. Status: Terminated.

Why it was recalled

This recall of LIPTRUZET is being initiated due to packaging defects. Some of the outer laminate foil pouches allowed in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product.

Product description

Liptruzet (ezetimibe and atorvastin) tablets,10 mg/20 mg, a) 30 count blister (NDC 66582-321-30), b) 90 count blister (NDC 66582-321-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889

Lot numbers, UPCs & expiration codes

a) Liptruzet 10/20mg 30 count, 346353, 346354, Exp. 06/14; 351809, Exp. 07/14, 360530, Exp. 12/14. b) Liptruzet 10/20mg, 90 count, 346387, Exp. 06/14; 353185, Exp.12/14.

Where it was sold

Nationwide and Puerto Rico

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1310-2014
Classification
Class III
Status
Terminated
Recall initiated
Jan 13, 2014
FDA report date
May 14, 2014
Quantity
20,259 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Merck & Co Inc

Original FDA data

Every field from FDA enforcement report D-1310-2014, exactly as published.

Show all FDA fields
City
Whitehouse Station
State
NJ
Status
Terminated
Country
United States
Event ID
67344
Address
1 Merck Dr
Address (line 2)
P.O. Box 100
Code information
a) Liptruzet 10/20mg 30 count, 346353, 346354, Exp. 06/14; 351809, Exp. 07/14, 360530, Exp. 12/14. b) Liptruzet 10/20mg, 90 count, 346387, Exp. 06/14; 353185, Exp.12/14.
Postal code
08889-3400
Report date
May 14, 2014
Product type
Drugs
Recall number
D-1310-2014
Classification
Class III
Recalling firm
Merck & Co Inc
Product quantity
20,259 cartons
Termination date
Sep 2, 2015
Reason for recall
This recall of LIPTRUZET is being initiated due to packaging defects. Some of the outer laminate foil pouches allowed in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Liptruzet (ezetimibe and atorvastin) tablets,10 mg/20 mg, a) 30 count blister (NDC 66582-321-30), b) 90 count blister (NDC 66582-321-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889
Distribution pattern
Nationwide and Puerto Rico
Recall initiation date
Jan 13, 2014
Initial firm notification
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Center classification date
May 6, 2014

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1310-2014, published May 14, 2014. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls